Indication

ROS1 positive non-small cell lung cancer

ROS1-positive non-small cell lung cancer is a distinct molecular subtype of epithelial lung malignancy characterized by chromosomal rearrangements or fusions involving the *ROS1* receptor tyrosine kinase gene. Read more about ROS1 positive non-small cell lung cancer

6 drugs 6 manufacturers

Advertisement

Drugs that treat it

Common ROS1 positive non-small cell lung cancer therapies.

Showing 1–6 of 6 drugs

XALKORI (crizotinib)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER·+3
Parke-Davis Pfizer

ROZLYTREK (entrectinib)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ROS1 POSITIVE NON-SMALL CELL LUNG CANCER·+1
GENENTECH

XALKORI (crizotinib)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER·+3
Laboratories Div

AUGTYRO (repotrectinib)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ROS1 POSITIVE NON-SMALL CELL LUNG CANCER·+1
BMS PRIMARYCARE

JIDEYTRO (zidesamtinib)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ROS1 POSITIVE NON-SMALL CELL LUNG CANCER
NUVALENT, INC.
Filter & compare in the drug finder →Opens the drug finder with ROS1 positive non-small cell lung cancer preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About ROS1 positive non-small cell lung cancer.

ROS1-positive non-small cell lung cancer is a distinct molecular subtype of epithelial lung malignancy characterized by chromosomal rearrangements or fusions involving the *ROS1* receptor tyrosine kinase gene.

These oncogenic fusions result in constitutively active chimeric kinase signaling that drives unchecked cellular proliferation and survival in pulmonary tissues.

This subtype typically presents as non-squamous non-small cell lung cancer, most commonly adenocarcinoma, and predominantly affects a demographic of younger individuals and patients with a light or never-smoking history.

Clinically, it frequently presents at an advanced or metastatic stage with a notable predilection for central nervous system involvement.

Personalize your experience

Follow ROS1 positive non-small cell lung cancer and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it